KBC Group
IMNM icon

KBC Group’s Immunome IMNM Stock Holding History

KBC Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60K Buy
+2,739
New +$61K ﹤0.01% 1585
2024
Q2 		– Sell
-1,011
Closed -$25K – 1882
2024
Q1 		$25K Buy
+1,011
New +$20.5K ﹤0.01% 1807

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

KBC Group's IMNM Position: Q1 2026 in Review

KBC Group opened a new position in Immunome (IMNM) in Q1 2026: 2,739 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #1585 among its holdings. This is a return to the name: KBC Group previously reported a position in IMNM as recently as Q1 2024.

KBC Group first reported a position in IMNM in Q1 2024 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • KBC Group held 2,739 shares of Immunome worth $60K as of Q1 2026.
  • Immunome was a new KBC Group position in Q1 2026.
  • Immunome made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1585 holding.
  • KBC Group first reported a position in Immunome in Q1 2024 and has held it in 2 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.